
|Articles|January 1, 2006
Experts weigh benefits, risks of Allergan-Inamed merger
National report — A proposed $3.2 billion merger of Botox-maker Allergan and breast-implant maker Inamed would ultimately benefit dermatologists, an Allergan official says.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
3
Introducing Dermatology Times NP/PA Connect
4
Narrow-Spectrum Sarecycline Approved for Moderate to Severe Acne in China
5











